Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-12-20
DOI
10.3389/fphar.2021.766125
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
- (2021) Benedetta Maria Bonora et al. Cardiovascular Diabetology
- Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
- (2021) Avivit Cahn et al. DIABETES CARE
- Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines
- (2021) Stefano Ciardullo et al. PHARMACOLOGICAL RESEARCH
- Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
- (2021) Thomas M. Caparrotta et al. Diabetes Therapy
- Effects of SGLT2 inhibitor on ischemic events stemming from atherosclerotic coronary diseases
- (2021) Gailin Ye et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study
- (2020) Tongtong Wang et al. Diabetes Therapy
- Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study
- (2020) Christie Rampersad et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
- (2020) Vikas S. Sridhar et al. DIABETES OBESITY & METABOLISM
- Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis
- (2020) Antonios Douros et al. ANNALS OF INTERNAL MEDICINE
- Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
- (2020) Yang Hu et al. Journal of Diabetes Research
- Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits
- (2020) Kristen Jackson et al. Current Osteoporosis Reports
- SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
- (2020) Katherine R. Tuttle et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
- (2019) Tadashi Toyama et al. DIABETES OBESITY & METABOLISM
- Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors
- (2019) Susan J. Bersoff-Matcha et al. ANNALS OF INTERNAL MEDICINE
- An update on the safety of SGLT2 inhibitors
- (2019) André J Scheen Expert Opinion On Drug Safety
- Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
- (2019) Zien Zhou et al. DIABETOLOGIA
- Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
- (2019) Yinghong Zhai et al. Journal for ImmunoTherapy of Cancer
- Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
- (2019) Gian Paolo Fadini et al. BMJ Open Diabetes Research & Care
- SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
- (2019) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
- (2018) Robert Puckrin et al. ACTA DIABETOLOGICA
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems
- (2017) E. Raschi et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
- (2017) Gian Paolo Fadini et al. Lancet Diabetes & Endocrinology
- SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
- (2016) Hiroyuki Ito et al. EXPERT OPINION ON PHARMACOTHERAPY
- Cerebral infarction and femoral venous thrombosis detected in a patient with diabetic ketoacidosis and heterozygous factor V Leiden G1691A and PAI-1 4G/5G mutations
- (2015) Selcen Yaroglu Kazanci et al. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database
- (2011) Jean-Louis Montastruc et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
- (2011) G Niklas Norén et al. STATISTICAL METHODS IN MEDICAL RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started